Original paper
AB0578 Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangitis
Volume: 73, Issue: Suppl 2, Pages: 997.1 - 997
Published: Jun 1, 2014
Abstract
Background
A double-blind, randomised, placebo-controlled, 60-week study of mepolizumab (300 mg every 4 weeks) in eosinophilic granulomatosis with polyangiitis (EGPA) is being sponsored by GlaxoSmithKline in collaboration with the National Institute of Allergy and Infectious Diseases (NIH) in the US. It is critical to ensure definition of the appropriate EPGA diagnostic criteria and study outcomes for this global study....Paper Details
Title
AB0578 Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangitis
Published Date
Jun 1, 2014
Volume
73
Issue
Suppl 2
Pages
997.1 - 997
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History